Lindsey Vanschoyck, NP
Acute Care · Los Altos Hills, CANPI 1083153878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $181 and has fallen 74.9% since, to $45 in 2024.
Across 32 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$114
- Exeltis, USA Inc.$96
- Myovant Sciences Inc.$74
- Sumitomo Pharma America, Inc.$49
- Therapeuticsmd, Inc.$45
- Axonics, Inc.$39
- plus $86 from 5 others
What the payments were for
- Food & beverage$504100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $114 |
| Exeltis, USA Inc. | 6 | $96 |
| Myovant Sciences Inc. | 5 | $74 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Therapeuticsmd, Inc. | 3 | $45 |
| Axonics, Inc. | 2 | $39 |
| Sage Therapeutics, LLC | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Shield Therapeutics Inc | 1 | $18 |
| Bayer | 1 | $15 |
| Organon | 1 | $6 |
How this compares
$504 in reported general payments places this provider in the 60th percentile of 1,153 acute care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 25 | $1,734 |
| Liothyronine Sodium | 26 | $1,047 |
| ProgesteroneProgesterone, Micronized | 25 | $843 |
| DottiEstradiol | 11 | $503 |
| Estradiol (Once Weekly)Estradiol | 11 | $289 |
| EnpresseLevonorgestrel/Ethin.Estradiol | 12 | $211 |
| Levothyroxine Sodium | 18 | $75 |
Paid to pharmacies, not to this prescriber.
Other acute care in Los Altos Hills
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.